Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lytic Cycle of Bacteriophages01:30

Lytic Cycle of Bacteriophages

70.4K
Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the...
70.4K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1
Antibiotic Selection00:57

Antibiotic Selection

52.4K
Overview
52.4K
Viral Replication: Lysogenic Cycle01:16

Viral Replication: Lysogenic Cycle

The lysogenic cycle is a crucial viral replication strategy that allows bacteriophages to persist within host cells without immediately destroying them. This process is primarily observed in temperate phages, such as bacteriophage lambda (λ), which infects Escherichia coli. The cycle allows the viral genome to persist across bacterial generations while keeping host cells viable.Integration of the Viral GenomeUpon infection, bacteriophage lambda attaches to the bacterial surface and injects...
Lysogenic Cycle of Bacteriophages00:43

Lysogenic Cycle of Bacteriophages

61.9K
In contrast to the lytic cycle, phages infecting bacteria via the lysogenic cycle do not immediately kill their host cell. Instead, they combine their genome with the host genome, allowing the bacteria to replicate the phage DNA along with the bacterial genome. The incorporated copy of the phage genome is called the prophage. Some prophages can re-activate and enter the lytic cycle. This often occurs in response to a perturbation, such as DNA damage, but can also transpire in the absence of...
61.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypoxia remodels circSTX6 nuclear export through URH49-ALYREF to drive IGF1-mediated bladder cancer progression.

Cellular signalling·2026
Same author

Towards modeling phage therapy.

PLoS computational biology·2026
Same author

Developing a mobile RNA delivery system for grafting trait improvement.

EMBO reports·2026
Same author

ZRANB1 promotes cell proliferation and lymph node metastasis through SF3B3-mediated alternative splicing of CHEK2 in urothelial bladder cancer.

Cell death & disease·2026
Same author

Seminiferous tubule-inspired coaxial bioprinting-derived extracellular vesicles restore Leydig cell steroidogenesis through modulation of Wnt4/β-catenin signaling.

Journal of nanobiotechnology·2026
Same author

Adolescent anodal tDCS ameliorates behavioral deficits and microglial abnormalities in a maternal immune activation mouse model of schizophrenia.

Psychopharmacology·2026

Related Experiment Video

Updated: Jun 9, 2025

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
07:22

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings

Published on: August 19, 2021

2.9K

Considerations for prioritising clinical research using bacteriophage.

Sarah J L Edwards1, Yiran Tao2, Rodas Elias3

  • 1STEaPP, University College London, 255309, Gower Street, London, U.K.

Essays in Biochemistry
|October 30, 2024
PubMed
Summary

Antimicrobial resistance (AMR) is a major health threat. Research priorities for bacteriophage therapy must balance global health impact with regulatory and researcher needs for effective AMR treatment.

Keywords:
Clinical trialsbacteriophagesfunding prioritiesregulation

More Related Videos

Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice
08:46

Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice

Published on: January 26, 2024

1.5K
Quantitative PCR of T7 Bacteriophage from Biopanning
05:42

Quantitative PCR of T7 Bacteriophage from Biopanning

Published on: September 27, 2018

10.7K

Related Experiment Videos

Last Updated: Jun 9, 2025

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
07:22

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings

Published on: August 19, 2021

2.9K
Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice
08:46

Author Spotlight: Investigating Bacteriophage-Induced Immune Responses in Gnotobiotic Mice

Published on: January 26, 2024

1.5K
Quantitative PCR of T7 Bacteriophage from Biopanning
05:42

Quantitative PCR of T7 Bacteriophage from Biopanning

Published on: September 27, 2018

10.7K

Area of Science:

  • Microbiology
  • Public Health
  • Biotechnology

Background:

  • Antimicrobial resistance (AMR) is a growing global health crisis, leading to increased mortality and healthcare costs.
  • Traditional antibiotics are losing efficacy, necessitating alternative treatments like bacteriophage therapy.
  • Prioritizing research for new AMR therapeutics is complex due to pathogen prevalence and treatment challenges.

Purpose of the Study:

  • To explore methods for setting research priorities for bacteriophage therapy against antibiotic-resistant pathogens.
  • To discuss the integration of bacteriophage therapy into mainstream medical practice.
  • To highlight the need for regulatory frameworks and data collection on safety and efficacy.

Main Methods:

  • Review of current methods for health priority setting (e.g., disability-adjusted life years).
  • Analysis of challenges posed by bacteriophage biology to standardization.
  • Discussion of regulatory considerations for novel therapeutics.

Main Results:

  • Existing priority-setting metrics may not fully capture the nuances of bacteriophage therapy development.
  • Biological characteristics of phages present unique challenges for universal prioritization.
  • Regulatory frameworks are crucial for integrating phage therapy and ensuring data collection.

Conclusions:

  • A balanced approach is needed to prioritize bacteriophage therapy research, considering both public health impact and scientific/regulatory feasibility.
  • Developing clear regulatory pathways is essential for advancing bacteriophage therapy.
  • Enhanced collective action and data generation are vital to combat AMR effectively.